EXHIBIT EVoting Agreement • May 14th, 2003 • MPM Bio Ventures Iii Lp • Pharmaceutical preparations • Delaware
Contract Type FiledMay 14th, 2003 Company Industry Jurisdiction
EXHIBIT DInvestor Rights Agreement • May 14th, 2003 • MPM Bio Ventures Iii Lp • Pharmaceutical preparations • California
Contract Type FiledMay 14th, 2003 Company Industry Jurisdiction
EXHIBIT BCommon Stock and Warrant Purchase Agreement • May 14th, 2003 • MPM Bio Ventures Iii Lp • Pharmaceutical preparations • California
Contract Type FiledMay 14th, 2003 Company Industry Jurisdiction
EXHIBIT AJoint Filing Agreement • May 14th, 2003 • MPM Bio Ventures Iii Lp • Pharmaceutical preparations
Contract Type FiledMay 14th, 2003 Company IndustryPursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of shares of stock of Rigel Pharmaceuticals, Inc.
EXHIBIT A JOINT FILING AGREEMENTJoint Filing Agreement • February 12th, 2009 • MPM Bioventures Iii Lp • Pharmaceutical preparations
Contract Type FiledFebruary 12th, 2009 Company IndustryIn accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of Somaxon Pharmaceuticals, Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.
EXHIBIT A JOINT FILING AGREEMENTJoint Filing Agreement • February 5th, 2015 • MPM Bioventures Iii L.P. • Pharmaceutical preparations
Contract Type FiledFebruary 5th, 2015 Company IndustryIn accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of KaloBios Pharmaceuticals, Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.
EXHIBIT A JOINT FILING AGREEMENTJoint Filing Agreement • February 13th, 2017 • MPM Bioventures Iii L.P. • Pharmaceutical preparations
Contract Type FiledFebruary 13th, 2017 Company IndustryIn accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of Vaccinogen, Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.